CPTX-2309: An In Vivo Engineered CAR-T Cell Therapy for Autoimmune Diseases

1. Executive Summary

CPTX-2309 is an investigational therapeutic agent being developed by Capstan Therapeutics, representing a novel approach to Chimeric Antigen Receptor T-cell (CAR-T) therapy. Unlike conventional CAR-T therapies that require ex vivo manipulation of a patient's T-cells, CPTX-2309 is designed to engineer CAR-T cells directly in vivo. This is achieved using Capstan's proprietary CellSeeker™ targeted lipid nanoparticle (tLNP) technology, which delivers a messenger RNA (mRNA) payload encoding an anti-CD19 CAR specifically to CD8-expressing T-cells.[1]

Preclinical studies, primarily in non-human primates (NHPs), have demonstrated that CPTX-2309 can lead to robust engineering of CD8+ CAR T-cells, resulting in rapid and profound depletion of B-cells in both blood and tissues.[1] Importantly, this B-cell depletion is followed by repopulation with predominantly naïve B-cells, suggesting the potential for an "immune reset" without the need for lymphodepleting chemotherapy, a common and often harsh prerequisite for ex vivo CAR-T treatments.[1] The transient nature of mRNA-driven CAR expression is anticipated to offer an improved safety profile compared to viral vector-based CAR-T therapies.[2]

Capstan Therapeutics is advancing CPTX-2309 into clinical development, with a Phase 1 study in healthy volunteers (NCT06917742) initiated to assess safety and tolerability.[5] The primary therapeutic focus for CPTX-2309 is B-cell mediated autoimmune diseases, leveraging the proof-of-concept established by ex vivo CD19 CAR-T therapies in these conditions.[3] If successful, CPTX-2309 could offer a significant advancement, potentially providing a more accessible, scalable, and safer CAR-T therapy option. This approach could not only transform the treatment of autoimmune disorders but also validate the broader applicability of targeted LNP-mRNA delivery for complex in vivo cell engineering beyond the liver, which has been a primary target for LNP-based therapies to date. The development of an effective "off-the-shelf" in vivo CAR-T system could substantially broaden patient access to this potent therapeutic modality.

2. Introduction to CPTX-2309: A Novel In Vivo CAR-T Therapy

2.1. Overview of CPTX-2309 and Developer (Capstan Therapeutics)

CPTX-2309 is the lead in vivo Chimeric Antigen Receptor T-cell (CAR-T) candidate under development by Capstan Therapeutics, Inc..[1] Capstan Therapeutics is a biotechnology company focused on advancing the in vivo reprogramming of cells through targeted RNA delivery utilizing its proprietary lipid nanoparticle (tLNP) platform, known as CellSeeker™.[1] The company's mission is to expand therapeutic possibilities by developing these targeted in vivo RNA technologies.[7] The advancement of CPTX-2309 and the broader tLNP pipeline is supported by significant financial backing, including a $175 million Series B financing round, which underscores investor confidence in this innovative approach to cell therapy.[3] This funding is a critical enabler for Capstan to progress CPTX2309 through early clinical trials and to further develop its versatile platform technology.

2.2. Therapeutic Class and Rationale

CPTX-2309 belongs to the therapeutic class of in vivo CAR-T therapies.[1] This classification signifies that the genetic modification of T-cells to express a CAR occurs directly within the patient's body. This is a departure from conventional ex vivo CAR-T therapies, which involve extracting a patient's T-cells, genetically engineering them in a laboratory setting, expanding them, and then re-infusing them into the patient.

The rationale behind developing CPTX-2309 is to merge the profound therapeutic potency of CAR-T cells, often described as a "living drug," with the favorable characteristics of traditional biologic therapies, such as convenience, scalability, pharmacological tunability, and predictability.[1] The development of CPTX-2309 aims to address several significant limitations associated with conventional ex vivo CAR-T therapies. These include the complex and costly manufacturing processes, challenges in patient access, the necessity for often harsh lymphodepletion regimens prior to cell infusion, and the considerable "vein-to-vein" time (the period from cell collection to reinfusion).[1] The explicit goal of combining the "potency of a living drug" with the "predictability of a biologic" [1] points to a fundamental challenge in the field of cell therapy: managing the inherent biological variability and the potential for uncontrolled or unpredictable responses associated with living cellular products. The use of mRNA for CAR expression in CPTX-2309, which leads to transient protein expression, is a key technological choice underpinning the aim for enhanced "predictability" and control over the therapeutic effect, distinguishing it from virally delivered CARs that integrate and express long-term.

Table 1: CPTX-2309 - Key Characteristics

Feature	Description
Drug Name	CPTX-2309
Developer	Capstan Therapeutics, Inc.
Technology Platform	CellSeeker™
Drug Class	In vivo CAR-T therapy
Molecular Target	CD19 (on B-cells)
Delivery Mechanism	CD8-targeted Lipid Nanoparticles (tLNPs) delivering mRNA encoding an anti-CD19 Chimeric Antigen Receptor
Therapeutic Goal	B-cell depletion, potential for immune system reset

3. The CellSeeker™ Technology Platform: Targeted RNA Delivery for In Vivo Cell Engineering

3.1. Description of Targeted Lipid Nanoparticles (tLNPs)

The foundation of CPTX-2309's innovative approach lies in Capstan Therapeutics' proprietary CellSeeker™ targeted lipid nanoparticle (tLNP) platform technology.[1] These tLNPs are engineered as non-viral delivery systems. A key feature of their design is the conjugation of a recombinant protein binder, such as a monoclonal antibody or an antibody fragment, to the surface of the lipid nanoparticle.[1] This targeting moiety is crucial for the platform's specificity.

The targeting mechanism relies on these surface-conjugated binders to facilitate preferential delivery of the LNP and its payload to specific cell types within the body. In the case of CPTX-2309, the tLNPs are designed with binders that target CD8, thereby directing the nanoparticles primarily to CD8-expressing T-cells.[1] An important characteristic of these LNPs is their designed rapid biodegradation, which is intended to allow for the possibility of re-dosing if clinically indicated, without concerns of long-term accumulation.[2]

3.2. mRNA Payload Delivery

The CellSeeker™ tLNPs are engineered to encapsulate and deliver various RNA-based payloads. These can include mRNA encoding for Chimeric Antigen Receptors (CARs), as is the case with CPTX2309, or potentially mRNA for other therapeutic proteins, or even RNA-guided gene editing tools.[1] Specifically for CPTX-2309, the tLNPs carry an mRNA payload that, once delivered into the target CD8+ T-cells, directs the synthesis of an anti-CD19 CAR.[1]

A significant advantage of using mRNA as the payload is the transient nature of the protein expression it produces. The CAR protein is synthesized by the cell's machinery for a limited period, after which the mRNA is degraded and protein expression ceases. This transient expression is hypothesized to improve the safety profile of the therapy, particularly by reducing the risks associated with long-term, uncontrolled CAR-T cell activity, while still being capable of driving durable therapeutic effects through mechanisms like immune reset.[2]

The modularity of the CellSeeker™ platform—comprising the LNP, the targeting binder, and the RNA payload—represents a considerable strength.[2] By altering the targeting binder, the tLNPs can, in principle, be redirected to different cell populations. Similarly, by changing the mRNA payload, a variety of therapeutic actions could be induced, such as expressing different CARs for oncology, enzymes for metabolic diseases, or components for in vivo gene editing. This inherent flexibility allows Capstan to envision applications across diverse therapeutic areas, including autoimmune diseases, oncology, fibrosis, and monogenic blood disorders, without needing to fundamentally re-engineer the core delivery technology for each new application.[1] Furthermore, the "rapid biodegradation" and "ability to re-dose" characteristics of the tLNPs are intrinsically linked to the choice of mRNA as a transient payload.[2] A delivery system that clears relatively quickly and can be administered multiple times is well-suited for an mRNA therapeutic, minimizing potential LNP-associated toxicities from accumulation and allowing for repeated therapeutic interventions if needed.

4. Mechanism of Action: Engineering CD8+ T-Cells for B-Cell Depletion and Immune System Reset

4.1. Targeting CD19 on B-Cells

The therapeutic strategy of CPTX-2309 revolves around the CD19 protein, which is broadly expressed on the surface of B-lymphocytes throughout their development, from early pro-B-cells to mature B-cells and plasma blasts, but is absent on hematopoietic stem cells and other cell lineages.[1] The mRNA payload delivered by CPTX-2309's tLNPs encodes a Chimeric Antigen Receptor (CAR) specifically designed to recognize and bind to this CD19 protein.[1] Once the CD8+ T-cells are engineered in vivo to express this anti-CD19 CAR, they become cytotoxic effector cells capable of identifying, engaging, and subsequently eliminating CD19-positive B-cells.[1]

4.2. In Vivo CAR-T Cell Generation

A hallmark of CPTX-2309 is its capacity for in vivo CAR-T cell generation. The CD8-targeted tLNPs deliver the anti-CD19 CAR-encoding mRNA preferentially to CD8-expressing cytotoxic T-lymphocytes directly within the patient's body.[1] This process effectively reprograms these T-cells, equipping them with the CAR necessary to target B-cells. Preclinical data indicates that this in vivo engineering leads to the generation of functional CD8+ anti-CD19 CAR T-cells.[3] This circumvents the need for ex vivo cell processing, a complex and resource-intensive step in conventional CAR-T therapies.

4.3. Goal of Immune Reset without Lymphodepletion

The primary therapeutic objective of CPTX-2309 in the context of autoimmune diseases is to achieve an "immune reset".[1] This process begins with the rapid and profound depletion of B-cells, including autoreactive B-cells, in both the peripheral blood and lymphoid tissues, mediated by the newly engineered in vivo CAR-T cells.[1] Following this depletion phase, the B-cell compartment is expected to repopulate. Preclinical evidence suggests this repopulation occurs predominantly with naïve B-cells, which are B-cells that have not yet encountered antigen and are therefore less likely to be autoreactive.[1] This shift in the B-cell repertoire towards a naïve state is the cornerstone of the "immune reset" concept, aiming to break the cycle of autoimmunity.

A critical differentiating feature of the CPTX-2309 approach is the goal of achieving this immune reset without the requirement for lymphodepleting chemotherapy.[1] Lymphodepletion, typically involving potent cytotoxic agents, is a standard component of ex vivo CAR-T therapy regimens, used to create space for and enhance the engraftment and proliferation of the infused CAR-T cells. However, it is associated with significant toxicities. By avoiding lymphodepletion, CPTX-2309 could offer a substantially improved safety and tolerability profile.

The mechanism can be visualized as a causal chain: the transient delivery of mRNA leads to transient CAR expression on CD8+ T-cells. These armed T-cells then execute targeted killing of CD19-expressing B-cells, resulting in a profound but temporary B-cell aplasia. This window of B-cell absence allows for the subsequent repopulation of the B-cell compartment, ideally with new, predominantly naïve B-cells, thereby potentially resetting B-cell-mediated autoimmune memory.[1] The transience of CAR expression is crucial here, as it allows for B-cell recovery and the desired reset, rather than causing permanent B-cell ablation which could lead to long-term immunosuppression.

If such an "immune reset," leading to durable, drug-free remission, can be reliably achieved with a transient, in vivo generated CAR-T therapy that does not require prior lymphodepletion, it would represent a revolutionary advance in the treatment of numerous B-cell mediated autoimmune diseases.[4] This approach could offer a potentially curative or long-term remission-inducing therapy with a significantly improved safety profile and greater patient accessibility compared to chronic immunosuppressive drugs or current ex vivo CAR-T regimens. The specific focus on engineering CD8+ cytotoxic T-cells is pivotal for achieving the "deep B cell depletion" observed preclinically.[1] CD8+ T-cells are naturally potent killer cells, and arming them directly with a CAR leverages their inherent cytotoxic capabilities for therapeutic benefit. The observed minimal engineering of CD4+ T-cells in preclinical models [3] may be an intentional and advantageous design feature. Uncontrolled CAR-CD4 T-cell activity could lead to complications such as excessive cytokine release or unpredictable immunomodulatory effects, so minimizing their involvement could contribute to an improved overall safety profile of the therapy.

5. Comprehensive Preclinical Evidence

5.1. In Vitro Studies: Efficacy in Healthy and Autoimmune Patient-Derived Cells

In vitro studies have provided foundational support for CPTX-2309's therapeutic concept. Capstan Therapeutics has reported that CPTX-2309 can effectively engineer CD8+ T-cells derived not only from healthy donors but also from patients diagnosed with a range of autoimmune diseases. These conditions include myositis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, Sjogren's syndrome, and multiple sclerosis.[1]

A particularly noteworthy finding from these in vitro experiments is that the efficiency of CD8+ T-cell engineering by CPTX2309 appears to be comparable between healthy donor cells and cells from autoimmune patients. Furthermore, this engineering capability was maintained even when T-cells were obtained from patients who had received prior therapies, including broadly utilized immunosuppressive agents.[1] This suggests a robustness of the technology in the face of potentially altered T-cell states due to underlying disease or concomitant medications. The CAR-T cells generated in vitro from these autoimmune patient samples subsequently demonstrated their functional capacity by effectively killing B-cells derived from the same patients.[1] The ability to effectively engineer T-cells from autoimmune patients, irrespective of common prior immunosuppressive treatments, is a highly significant preclinical observation. It suggests that CPTX2309 might retain its efficacy in real-world clinical settings where patients are often heavily pre-treated with drugs that can modulate T-cell function and numbers. This robust performance in vitro provides a strong rationale for expecting similar efficacy when CPTX2309 is administered in vivo to patients with complex immune environments.

5.2. Non-Human Primate (NHP) Studies

Extensive preclinical evaluation of CPTX-2309's in vivo activity has been conducted in non-human primates (NHPs), primarily cynomolgus macaques. These studies have been instrumental in understanding the pharmacodynamics, efficacy, and safety of the in vivo CAR-T engineering approach.

5.2.1. Use of CPTX2309-S (Anti-CD20 Surrogate)

A significant portion of the NHP research utilized CPTX2309-S, an agent that delivers an mRNA payload encoding an anti-CD20 CAR, as a surrogate for the anti-CD19 CAR delivered by CPTX2309.[3] The anti-CD20 CAR in CPTX2309-S was designed to be cross-reactive with NHP CD20. This surrogate was reported to exhibit comparable activity to CPTX2309 (anti-CD19) in in vitro assays.[4] The use of an anti-CD20 surrogate in NHPs is a common strategy in preclinical CAR-T development, often due to better availability of cross-reactive reagents or specific characteristics of CD20 expression and biology in these models that facilitate robust B-cell depletion readouts.

5.2.2. Pharmacodynamics: CD8+ T-Cell Engineering and Kinetics

Treatment with CPTX2309 (or its surrogate CPTX2309-S) in NHP models resulted in robust and preferential engineering of functional CD8+ CAR T-cells in vivo.[1] Reports indicate that up to 80-90% of circulating CD8+ T-cells were successfully reprogrammed to express the CAR following administration.[3] While CD8+ T-cells were the primary target, CAR expression was also observed on CD8+ natural killer (NK) cells and monocytes.[3] Importantly, minimal CAR engineering was detected in CD4+ T-cells and B-cells, highlighting the preferential targeting of the CD8-directed tLNPs.[3] Consistent with the transient nature of mRNA delivery, the CAR T-cell engineering was also observed to be transient.[4]

5.2.3. Efficacy: B-Cell Depletion in Blood and Tissues

The engineered CAR-T cells demonstrated potent efficacy in depleting B-cells. Rapid and profound, often complete, depletion of B-cells was observed in the peripheral blood of NHPs, with effects seen as early as 6 hours after the first dose of CPTX2309-S, even at low doses such as 0.1 mg/kg.[1] This depletion extended beyond the circulation, with studies showing global depletion of B-cells in lymphoid tissues, including the bone marrow, spleen, and lymph nodes, by approximately day 10 post-treatment initiation.[3] The extent of tissue B-cell depletion was dose-dependent, with comparable deep depletion achieved at CPTX2309-S doses of 0.5 mg/kg and higher when administered in a multi-dose regimen.[4]

5.2.4. B-Cell Repopulation Dynamics

Following the period of profound B-cell depletion, recovery of the B-cell compartment was observed in NHPs, typically beginning within 2-3 weeks after the depletion phase.[4] In one study cohort, B-cell recovery commenced within three weeks in five out of six animals treated with an effective two-dose regimen.[3] A key characteristic of this B-cell repopulation was the phenotype of the emerging B-cells. The repopulating B-cell pool was predominantly composed of naïve B-cells (often characterized as CD27- IgD+), with very few post-switch memory B-cells (e.g., CD27+ IgD-).[1] This pattern, suggestive of an "immune reset," was reported to persist, with the B-cell profile remaining skewed towards naïve cells for the duration of the observation period (e.g., up to six weeks in some studies).[3]

5.2.5. Dosing Regimen Exploration

Preclinical NHP studies explored various dosing regimens to optimize the in vivo CAR-T engineering and B-cell depletion. A consistent finding appears to be that a regimen involving two or more infusions of CPTX2309 (or CPTX2309-S) was more effective than a single high dose. For example, a two-infusion regimen with doses administered 3 days apart, or a compact regimen of three doses administered every 72 hours (3x q72hr), resulted in rapid and deep B-cell depletion.[3] Conversely, a single dose of 2 mg/kg was reported to be less effective in achieving global B-cell depletion compared to two lower-dose infusions (e.g., 1 mg/kg, 1.5 mg/kg, or a step-up dosing strategy).[3] The dose range for CPTX2309-S evaluated in these NHP studies generally spanned from 0.1 mg/kg to 1.5 mg/kg per dose.[4] This NHP data consistently indicating that multiple lower doses are superior to a single high dose for achieving comprehensive B-cell depletion is quite telling.[3] Given that mRNA is a transient molecule, multiple administrations likely serve to maintain a therapeutically effective level of CAR expression on T-cells for a longer duration. This sustained presence of armed effector cells allows for more thorough targeting and elimination of B-cells throughout various bodily compartments, a dynamic that differs significantly from virally delivered CAR-T therapies where a single administration typically leads to long-term, persistent CAR expression.

5.3. Preclinical Safety and Tolerability

The preclinical safety profile of CPTX2309-S in NHPs was reported to be excellent, particularly at doses of 0.1 – 1.0 mg/kg administered in a three-dose regimen.[4] A crucial aspect highlighted in the preclinical data is that the observed efficacy, including profound B-cell depletion, was achieved without the need for prior lymphodepletion chemotherapy.[1] This is a significant potential advantage over traditional ex vivo CAR-T therapies. The observation of CAR expression on CD8+ NK cells and monocytes in NHPs [4], although CD8+ T-cells are the intended primary target, warrants careful monitoring in human trials. While these cells might also contribute to B-cell depletion, any off-target transfection could potentially lead to unintended immunological effects. The "minimal" engineering reported in CD4+ T-cells is a positive indicator for the specificity of the CD8-targeting approach. The upcoming Phase 1 clinical trial will be critical in thoroughly assessing cell-type specificity and the overall safety profile in humans.

Table 2: Summary of Key Preclinical Findings for CPTX-2309 and CPTX2309-S (NHP Studies)

Parameter	Finding	Source(s)
Model	Non-Human Primate (Cynomolgus Macaque)	4
Agent(s)	CPTX2309-S (anti-CD20 CAR mRNA surrogate); CPTX2309 (anti-CD19 CAR mRNA) implications	3
Dosing Regimen(s) Evaluated	0.1-1.5 mg/kg CPTX2309-S; single vs. multiple infusions (e.g., 3x q72hr, two infusions 3 days apart)	3
CD8+ T-cell CAR Expression	Up to 80-90%; transient	3
CD4+ T-cell CAR Expression	Minimal	3
Other Cell CAR Expression	Observed on CD8+ NK cells and monocytes	3
B-cell Depletion (Blood)	Rapid (as early as 6h post-1st dose), complete/deep	1
B-cell Depletion (Tissues)	Deep, dose-dependent (bone marrow, spleen, lymph nodes)	3
B-cell Repopulation	Began 2-3 weeks post-depletion; predominantly naïve B-cells (CD27- IgD+)	1
Key Safety Observations	Excellent safety and tolerability profile at 0.1–1.0 mg/kg x3 (CPTX2309-S); achieved without lymphodepletion	1

6. Clinical Development Program and Regulatory Outlook

6.1. Phase 1 Clinical Trial in Healthy Volunteers (NCT06917742)

CPTX-2309 has entered the clinical phase of development with a first-in-human study. The trial, identified as NCT06917742 and titled "A Study of CPTX2309 in Healthy Participants," is designed to evaluate the initial safety and tolerability of the investigational drug.[1] As of early April 2025, the trial was listed with a status of "Not yet recruiting".[3]

This Phase 1 study is an open-label trial, meaning both researchers and participants will be aware of the treatment being administered.[5] It is structured with two main parts: a Single Ascending Dose (SAD) component, where participants receive a single intravenous dose of CPTX2309, and a Multiple Ascending Dose (MAD) component, where participants will receive multiple intravenous doses over a defined period.[5] The study aims to enroll an estimated 38 healthy adult participants, both male and female, aged between 18 and 55 years.[5] Key exclusion criteria include evidence of organ dysfunction or the use of other investigational drugs within 30 days or 5 half-lives prior to CPTX2309 administration.[5]

The primary purpose of NCT06917742 is to rigorously assess the safety and tolerability of CPTX2309 when administered intravenously.[5] Participants will be closely monitored throughout the study for any potential side effects or adverse reactions. The study is being conducted at Nucleus Network Brisbane, in Herston, Queensland, Australia.[1] There is a slight discrepancy in the publicly listed estimated study completion dates, with some sources indicating April 10, 2025 [5], and another suggesting February 1, 2026 [1]; the later date is often a more conservative estimate for planning purposes. Capstan Therapeutics, Inc. is the sponsor of this clinical trial.[3]

The decision to conduct the first-in-human study in healthy volunteers, rather than directly in patients with autoimmune diseases, reflects a cautious and methodical approach to evaluating a novel in vivo cell engineering technology.[5] This strategy allows for the characterization of CPTX2309's pharmacokinetic and pharmacodynamic profiles, as well as its initial tolerability, in a "clean" biological system before progressing to more complex patient populations who may have active disease and be receiving concomitant medications. The SAD/MAD design is a standard and robust methodology for early-phase clinical trials of novel therapeutic agents.

6.2. Projected Timelines for Patient Studies

Based on the promising preclinical data, Capstan Therapeutics has indicated plans to advance CPTX-2309 into clinical trials involving patients with autoimmune diseases by mid-2025.[1] This timeline suggests that the company is actively working towards subsequent phases of clinical development beyond the initial healthy volunteer study.

6.3. Regulatory Outlook (IND Status, Orphan Drug Designation, Fast Track)

The provided research materials do not explicitly state that an Investigational New Drug (IND) application for CPTX-2309 has been cleared by the U.S. Food and Drug Administration (FDA) or similar regulatory authorities like Australia's Therapeutic Goods Administration (TGA). However, one press release mentioned that preclinical data "set the stage for clinical evaluation of CPTX2309," which implies that IND-enabling studies are likely complete or nearing completion, and regulatory submissions are a forthcoming or ongoing step.[11] The initiation of a Phase 1 trial in Australia (NCT06917742) indicates that regulatory approval for that specific trial has been obtained from the relevant Australian authorities. It is common for biotechnology companies to pursue global development strategies, and conducting early-phase trials in regions like Australia can be part of this, potentially preceding or running in parallel with U.S. FDA processes. The "excellent safety and tolerability profile in NHPs" [4] and the ability to achieve therapeutic effects "without lymphodepletion chemotherapy" [1] are crucial preclinical findings that would strongly support the progression to Phase 1 trials and are likely foundational to the proposed safety evaluation in healthy volunteers.

There is no information within the provided snippets to suggest that CPTX-2309 has received Orphan Drug Designation or Fast Track status from the FDA or other regulatory bodies. Discussions of such designations in the source material pertained to other companies' drug candidates.[13]

Table 3: Overview of Clinical Trial NCT06917742

Feature	Details
Trial Identifier	NCT06917742
Phase	Phase 1
Title	A Study of CPTX2309 in Healthy Participants
Status (as of April 2025)	Not yet recruiting
Study Population	Healthy adult volunteers (male and female), N=38 (estimated), ages 18 to 55 years
Intervention(s)	CPTX2309, administered intravenously. Includes Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts.
Primary Outcome Measures	Assessment of safety and tolerability of CPTX2309.
Key Secondary Outcome Measures	Likely to include pharmacokinetics of CPTX2309 and pharmacodynamic markers (e.g., B-cell counts, detection of CAR T-cells, cytokine levels, though not explicitly detailed for healthy volunteers in snippets).
Sponsor	Capstan Therapeutics, Inc.
Location(s)	Nucleus Network Brisbane, Herston, Queensland, Australia
Estimated Study Completion	February 1, 2026 (per 1); note discrepancy with April 10, 2025 (per 5).

7. Therapeutic Potential and Target Indications

7.1. Primary Focus: B-Cell Mediated Autoimmune Diseases

The primary therapeutic development path for CPTX-2309 is focused on a potentially broad range of B-cell-mediated autoimmune diseases.[3] The rationale for this focus stems from the critical role of B-cells in the pathogenesis of these conditions, both as antibody producers and as antigen-presenting cells that can perpetuate autoimmune responses. The ability of CPTX-2309 to induce deep B-cell depletion, followed by a repopulation skewed towards naïve B-cells, offers the prospect of an "immune reset".[1]

Capstan Therapeutics has presented in vitro data demonstrating that CPTX2309 can effectively engineer CD8+ T-cells obtained from patients with several specific autoimmune diseases. These include myositis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, Sjogren's syndrome, and multiple sclerosis (MS).[1] The engineered T-cells from these patients were subsequently shown to be capable of killing B-cells from the same individuals. This provides direct, albeit preclinical, evidence of CPTX2309's potential activity in the context of these challenging diseases. The overarching therapeutic goal for CPTX2309 in autoimmunity is to achieve a durable, drug-free clinical response or remission by fundamentally altering the patient's B-cell repertoire.[3]

The choice of autoimmune diseases as the initial clinical target for an anti-CD19 CAR-T therapy like CPTX2309 is strategically sound. It leverages emerging and compelling clinical evidence from academic-led studies of ex vivo CD19 CAR-T therapies in conditions such as refractory SLE, where profound and durable remissions have been observed.[1] This existing body of work provides a degree of target validation for CD19-directed B-cell depletion in autoimmunity and offers a clearer pathway for CPTX2309 to demonstrate clinical proof-of-concept for its novel in vivo platform. Capstan is essentially building upon this scientific momentum, aiming to deliver similar or improved therapeutic outcomes with a potentially safer, more convenient, and more accessible in vivo approach. This positions CPTX2309 well within the growing trend of exploring CAR-T therapies beyond their initial successes in oncology, particularly for severe autoimmune diseases where current treatments are often palliative or associated with significant long-term toxicities.

7.2. Exploratory Applications: Oncology, Fibrosis, Monogenic Blood Disorders

While autoimmune diseases represent the lead indication area, Capstan Therapeutics envisions broader applicability for its CellSeeker™ tLNP technology and the in vivo CAR-T approach. Potential exploratory applications extend into oncology, fibrosis, and monogenic blood disorders.[1] The inherent modularity of the platform, allowing for changes in both the targeting binder and the RNA payload, underpins this versatility.

For instance, in oncology, the platform could be adapted to generate CAR-T cells targeting tumor-specific antigens. For monogenic blood disorders, the CellSeeker™ technology could potentially be used for the in vivo delivery of gene editing payloads (e.g., CRISPR/Cas systems encoded by mRNA) to hematopoietic stem cells, aiming to correct the underlying genetic defects.[2] Success in autoimmune diseases with CPTX2309 could therefore pave the way for the development of CPTX2309 itself (or similar anti-CD19 constructs) in B-cell malignancies. More broadly, it would validate the platform's capacity for safe and efficient targeted delivery to specific cell types in vivo, opening doors for a wide array of genetic and cellular therapies. This suggests a long-term strategic vision for Capstan that extends well beyond CAR-T cells for autoimmunity.

8. Comparative Landscape and Future Perspectives

8.1. Advantages Over Conventional Ex Vivo CAR-T Therapies

CPTX-2309, as an in vivo CAR-T engineering platform, is designed to offer several significant advantages over conventional ex vivo CAR-T therapies, which, despite their efficacy, face considerable logistical and clinical challenges:

• No Requirement for Lymphodepletion Chemotherapy: One of the most clinically impactful potential advantages is the ability to achieve therapeutic effects without the need for prior lymphodepleting chemotherapy.[1] This would spare patients from the toxicities associated with these conditioning regimens.
• Scalable and Simplified Manufacturing: The technology aims to eliminate the complex, patient-specific, and costly ex vivo cell manufacturing processes.[1] CPTX-2309 is designed as a more traditional pharmaceutical product.
• "Off-the-Shelf" Availability: As a non-cellular, non-viral product, CPTX-2309 could be available "off-the-shelf," similar to standard biologics. This would eliminate the lengthy vein-to-vein waiting period characteristic of autologous ex vivo CAR-T therapies.[2]
• Tunable Dosing and Re-dosability: The pharmacological properties of an LNP-mRNA product allow for tunable dosing to achieve the desired balance of safety and efficacy.[2] The ability to re-dose, facilitated by the biodegradable nature of the LNPs and transient mRNA expression, offers flexibility not easily achieved with viral CAR-T approaches.[2]
• Improved Safety Profile: The transient expression of CARs mediated by mRNA, as opposed to permanent genetic modification with viral vectors, is anticipated to lead to an improved safety profile, potentially reducing risks of long-term CAR-T persistence, insertional mutagenesis (though rare with current vectors), and chronic B-cell aplasia.[2]
• Enhanced Patient Access and Improved Benefit-Risk: Collectively, these features could lead to an improved overall benefit-risk profile and significantly increase patient access to CAR-T based therapies.[2]

The combination of "no lymphodepletion" and "off-the-shelf" availability, if realized, would confer a dramatic logistical and patient-experience advantage for CPTX2309 over existing ex vivo CAR-T therapies.[2] Current ex vivo CAR-T administration is a multi-step, weeks-long process involving apheresis, cell shipping, centralized manufacturing, patient conditioning with chemotherapy, and finally, cell reinfusion, typically restricted to specialized academic medical centers. An off-the-shelf product that can be administered intravenously like a standard biologic, without the need for prior lymphodepletion, could potentially shift CAR-T therapy from these highly specialized settings into broader clinical practice, making it accessible to a much larger patient population.

8.2. Potential Impact and Unmet Needs Addressed

CPTX-2309 holds the potential to transform the treatment landscape for severe B-cell-mediated autoimmune diseases by offering a therapy aimed at inducing durable, drug-free remission. Many of these conditions currently lack curative options, and patients often rely on long-term immunosuppressive therapies that have incomplete efficacy and significant side effects. CPTX-2309 addresses the substantial unmet medical need for safer, more accessible, and potentially definitive treatment options in autoimmunity.

The "tunable dosing" and "re-dosing" capabilities inherent in an LNP-mRNA platform could also allow for more personalized and adaptive treatment strategies.[2] For example, clinicians might employ an initial induction phase to achieve deep B-cell depletion, followed by maintenance doses if B-cell repopulation leads to signs of disease recurrence. Alternatively, dose intensity could be tailored based on individual patient characteristics, disease burden, or specific biomarkers. This flexibility represents a significant departure from the often "one and done" administration paradigm of current virally delivered CAR-T therapies and could allow for more nuanced long-term disease management.

9. Key Scientific Communications and Data Disclosures

Capstan Therapeutics has been actively disseminating preclinical data on CPTX-2309 and its underlying CellSeeker™ platform at major international scientific conferences. These presentations have provided insights into the technology, its mechanism of action, and the progressive development of the lead candidate.

Key presentations include:

• American College of Rheumatology (ACR) Convergence 2024 (Washington D.C.): Multiple presentations detailed preclinical data for CPTX2309 and its NHP surrogate, CPTX2309-S. These covered NHP studies showing B-cell depletion and repopulation dynamics indicative of an immune reset, as well as in vitro data on the effective engineering of T-cells from autoimmune disease patients.[1] Specific abstract identifiers mentioned were 0835 ("Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid Nanoparticle Encoding an Anti-CD19 CAR mRNA (CPTX2309)"), 0088 ("Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR"), and 0019 ("A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles").[7]
• American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting (May 13-17, 2025, New Orleans): Planned oral presentations include data on a two-infusion regimen of CPTX2309 in NHPs achieving up to 90% CD8+ T-cell engineering and tissue depletion of target cells, and a broader presentation on in vivo immune cell engineering using targeted nanoparticles.[3]
• Cellicon Valley '25 (April 30-May 2, 2025, Philadelphia): An oral presentation by Capstan's CEO was scheduled, titled "Leading the Charge for In Vivo Cell Therapy for The Treatment of Autoimmune Disorders".[11]
• International Society of Cell & Gene Therapy (ISCT) 2025 (May 7-10, 2025, New Orleans): A poster presentation was planned on the "Design and Preclinical Development of a Novel In Vivo Chimeric Antigen Receptor (CAR) Product for B-Cell Involved Diseases".[11]
• 21st Annual PEGS Boston: The Essential Protein & Antibody Engineering Summit (May 12-16, 2025, Boston): Capstan's CSO was slated to provide Chairperson's Remarks for the track on "In Vivo CAR T Engineering: Moving into the Clinic".[11]
• TIDES USA: Oligonucleotide and Peptide Therapeutics (May 19-22, 2025, San Diego): An oral presentation by Capstan's CTO was scheduled, titled "In Vivo Engineering of Cells Using Targeted Lipid Nanoparticles".[11]

This consistent and expanding presence at leading immunology, gene therapy, and cell therapy conferences signifies a deliberate strategy by Capstan Therapeutics to engage with the scientific and medical communities.[1] Such engagement is crucial for building validation for their novel platform and lead candidate. The progression of presentation topics, from foundational platform technology and early NHP data to more detailed regimen explorations and forward-looking statements about clinical trial plans, illustrates a maturing research and development program. These disclosures allow for peer scrutiny, facilitate scientific exchange, and increase visibility, all of which are important for a company pioneering cutting-edge therapeutic technologies.

Table 4: Key Scientific Presentations for CPTX-2309

Conference	Date(s)	Abstract/Presentation Title/Focus	Presenting Author(s) (from Capstan)	Source(s)
ACR Convergence 2024	Nov 2024	NHP B-cell depletion/repopulation (CPTX2309-S); Engineering of autoimmune patient T-cells in vitro (CPTX2309); Platform overview. (Abstracts: 0019, 0088, 0835)	Haig Aghajanian, Aric Frantz, Theresa Hunter	4
Cellicon Valley '25	Apr 30-May 2, 2025	"Leading the Charge for In Vivo Cell Therapy for The Treatment of Autoimmune Disorders"	Laura Shawver	11
ISCT 2025	May 7-10, 2025	"Design and Preclinical Development of a Novel In Vivo Chimeric Antigen Receptor (CAR) Product for B-Cell Involved Diseases" (Poster 901)	Haig Aghajanian	11
PEGS Boston 2025	May 12-16, 2025	Chairperson's Remarks: "In Vivo CAR T Engineering: Moving into the Clinic"	Adrian Bot	11
ASGCT 28th Annual Meeting	May 13-17, 2025	"A Two-Infusion Regimen with a Novel In Vivo Non-Viral Chimeric Antigen Receptor (CAR) Achieves up to 90% CD8+ T Cell Engineering and Tissue Depletion of Target Cells in Non-Human Primates (NHPs)"	Haig Aghajanian	11
ASGCT 28th Annual Meeting	May 13-17, 2025	Science Symposium: "In vivo immune cell engineering using targeted nanoparticles"	Priya Karmali	11
TIDES USA 2025	May 19-22, 2025	"In Vivo Engineering of Cells Using Targeted Lipid Nanoparticles"	Priya Karmali	11

10. Expert Analysis and Conclusion

CPTX-2309 represents a significant and innovative step forward in the field of cell therapy, particularly with its in vivo CAR-T engineering approach. The utilization of Capstan Therapeutics' CellSeeker™ tLNP platform to deliver anti-CD19 CAR-encoding mRNA specifically to CD8+ T-cells is built on a strong scientific rationale. The preclinical evidence, especially from NHP studies, is compelling, demonstrating robust CD8+ T-cell engineering, profound and rapid B-cell depletion, and, crucially, a subsequent repopulation of the B-cell compartment with predominantly naïve cells.[1] This latter observation supports the therapeutic goal of achieving an "immune reset," which holds considerable promise for B-cell-mediated autoimmune diseases.

The potential to achieve these effects transiently, due to the nature of mRNA, and without the need for harsh lymphodepletion chemotherapy, addresses some of the most significant limitations of current ex vivo CAR-T therapies, namely safety, complexity, cost, and patient accessibility.[1] If these advantages translate successfully to human clinical trials, CPTX-2309 could redefine the treatment paradigm for a host of severe autoimmune conditions.

However, several potential challenges and unanswered questions remain as CPTX-2309 transitions into and through clinical development. The translation of efficacy and safety findings from NHP models to human subjects is never guaranteed, and species-specific differences in immune response and LNP biodistribution can play a role. Optimizing dosing regimens—including dose levels, frequency, and duration of treatment—will be critical in diverse human patient populations with varying degrees of disease activity and immune dysregulation. While transient CAR expression is a designed safety feature, the long-term durability of the "immune reset" and the ensuing clinical remission in autoimmune patients can only be determined through extended follow-up in patient trials. The NHP studies provide encouraging early data on naïve B-cell repopulation [4], but the duration of this effect and its correlation with sustained absence of autoreactivity are key questions. Furthermore, the potential for immunogenicity to components of the tLNP or the CAR construct itself, particularly with re-dosing, will need careful evaluation, as this could impact both safety and long-term efficacy.

The initiation of the Phase 1 clinical trial in healthy volunteers (NCT06917742) is a critical next step.[5] Data from this study regarding safety, tolerability, the pharmacokinetics of the tLNPs, and any measurable pharmacodynamic markers (such as transient changes in B-cell populations, detection of CAR-expressing T-cells, and cytokine profiles even in a healthy system) will be paramount. These findings will heavily influence the design of subsequent trials in patients with autoimmune diseases and provide the first human validation of this in vivo engineering approach.

In conclusion, CPTX-2309 stands out as a highly promising therapeutic candidate. Its innovative in vivo CAR-T generation mechanism, underpinned by the versatile CellSeeker™ tLNP-mRNA platform, offers a scientifically robust strategy to address significant unmet needs in autoimmune disease treatment. While clinical development will present its own set of challenges, the strong preclinical data package and the clear potential to overcome major hurdles associated with current cell therapies position CPTX-2309 as a candidate with transformative potential. If its preclinical promise is realized in human trials, CPTX-2309 could herald a new era of more accessible, safer, and potentially curative cell therapies for a wide range of debilitating autoimmune disorders, and further validate the CellSeeker™ platform for broader applications in in vivo cell and gene therapy.

Works cited

1. Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024, accessed May 19, 2025, https://www.capstantx.com/press-releases/capstan-therapeutics-presents-preclinical-data-on-lead-in-vivo-car-t-candidate/
2. Science & Platform - Capstan Therapeutics, accessed May 19, 2025, https://www.capstantx.com/science-platform/
3. CPTX2309 / Capstan Therap - Larvol Delta, accessed May 19, 2025, https://delta.larvol.com/Products/?ProductId=4438c5ec-8cab-41c8-ad1f-28e72fdc8388
4. Profound B Cell Depletion and Repopulation with Predominantly ..., accessed May 19, 2025, https://acrabstracts.org/abstract/profound-b-cell-depletion-and-repopulation-with-predominantly-naive-b-cells-in-non-human-primates-achieved-through-a-novel-in-vivo-cd8-targeted-lipid-nanoparticle-mrna-car/
5. A Study of CPTX2309 in Healthy Participants | TrialScreen, accessed May 19, 2025, https://app.trialscreen.org/trials/phase-1-cptx2309-healthy-participants-trial-nct06917742
6. A Study of CPTX2309 in Healthy Participants - ClinicalTrials.Veeva, accessed May 19, 2025, https://ctv.veeva.com/study/a-study-of-cptx2309-in-healthy-participants
7. Capstan Therapeutics to Present Preclinical Data on Lead In Vivo Chimeric Antigen Receptor (CAR)-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024 | Business Wire, accessed May 19, 2025, https://www.businesswire.com/news/home/20240926582224/en/Capstan-Therapeutics-to-Present-Preclinical-Data-on-Lead-In-Vivo-Chimeric-Antigen-Receptor-CAR--T-Candidate-CPTX2309-at-American-College-of-Rheumatology-ACR-Convergence-2024
8. Capstan Therapeutics to Present Preclinical Data on Lead In Vivo Chimeric Antigen Receptor (CAR)-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024 - KitchenSinq, accessed May 19, 2025, https://kitchensinq.q4ir.com/investors/news/press-release-details/2024/Capstan-Therapeutics-to-Present-Preclinical-Data-on-Lead-In-Vivo-Chimeric-Antigen-Receptor-CAR-T-Candidate-CPTX2309-at-American-College-of-Rheumatology-ACR-Convergence-2024/default.aspx
9. Allogeneic cell therapies “poised for prime time” says expert - Pharmaceutical Technology, accessed May 19, 2025, https://www.pharmaceutical-technology.com/news/allogeneic-cell-therapies-poised-for-prime-time-says-expert/
10. Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024 - Business Wire, accessed May 19, 2025, https://www.businesswire.com/news/home/20241118858480/en/Capstan-Therapeutics-Presents-Preclinical-Data-on-Lead-In-Vivo-CAR-T-Candidate-CPTX2309-at-American-College-of-Rheumatology-ACR-Convergence-2024
11. Capstan Therapeutics to Participate in Upcoming Scientific Conferences and Present New Preclinical Data in Support of Lead Anti-CD19 In Vivo CAR-T Candidate, CPTX2309 - Business Wire, accessed May 19, 2025, https://www.businesswire.com/news/home/20250430109979/en/Capstan-Therapeutics-to-Participate-in-Upcoming-Scientific-Conferences-and-Present-New-Preclinical-Data-in-Support-of-Lead-Anti-CD19-In-Vivo-CAR-T-Candidate-CPTX2309
12. Error | ClinicalTrials.gov, accessed May 19, 2025, https://clinicaltrials.gov/study/NCT06917742
13. U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics' Proprietary Radiopharmaceutical Cancer Therapy, accessed May 19, 2025, https://ariceum-therapeutics.com/u-s-fda-grants-orphan-drug-designation-to-ariceum-therapeutics-proprietary-radiopharmaceutical-cancer-therapy/
14. FDA grants Orphan Drug Designation to Ariceum cancer therapy - PharmaTimes, accessed May 19, 2025, https://pharmatimes.com/news/fda-grants-orphan-drug-designation-to-ariceum-cancer-therapy/
15. Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - BioSpace, accessed May 19, 2025, https://www.biospace.com/press-releases/following-positive-phase-2-results-and-orphan-drug-designation-biodexas-fap-drug-receives-fda-fast-track-status
16. News & Publications | Capstan Therapeutics, accessed May 19, 2025, https://www.capstantx.com/news-publications/